Skip to content

Biomodulator Patch for Subjective Tinnitus

Effect of a Dermal Biomodulator Patch on Subjective Tinnitus: a Randomized, Double-blind, Placebo-controlled Trial With 1-year Follow-up

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07731230
Enrollment
91
Registered
2026-07-28
Start date
2018-06-12
Completion date
2021-02-27
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperacusis, Tinnitus

Keywords

Tinnitus, Biomodulator patch, Hyperacusis

Brief summary

This study tested whether a skin patch, worn behind the ear, could help reduce tinnitus (ringing or buzzing in the ears) in adults. Eighty participants took part. Half wore an active patch, and half wore a patch that looked the same but had no active effect (a placebo). Neither the participants nor the researchers knew who received which patch until the study ended. All participants also received an educational counseling session about tinnitus and how to manage it. Participants were assessed before treatment, three weeks later, about seven weeks later, and again about one year later. The researchers measured how much tinnitus affected their daily life, their sensitivity to sound, and their anxiety or mood.

Detailed description

Tinnitus is a common condition without a universally accepted pharmacological treatment. The steady-state coherent biomodulator patch (Antinitus, Sensori AB, Sweden) uses passive, light photon-driven technology intended to influence water coherency in tissue and modulate neural activity along auditory pathways. Its performance and safety have previously been evaluated in earlier randomized controlled trials and post-market surveys, with follow-up data reported up to one year after treatment in prior literature. This single-center, randomized, double-blind, placebo-controlled trial evaluated the clinical effectiveness of the biomodulator patch in adults with subjective tinnitus, examining both short-term and long-term (up to one year) outcomes. Participants were randomly assigned to receive either the active patch or a visually identical placebo patch, applied behind the ear and replaced daily for three weeks. Active and placebo patches were distributed in sealed envelopes to preserve blinding; neither participants nor investigators were aware of group allocation during the trial. All participants received a standardized informative counseling session at study entry (approximately one hour), covering the auditory system, the nature and causes of tinnitus, available management approaches, and instruction on correct patch application. Assessments were conducted at baseline, after 21 days of treatment, one month after treatment completion (day 51), and via telephone follow-up at approximately one year post-treatment. Continuous data are summarized as median and interquartile range given non-normal distributions. Within-group longitudinal changes were assessed using Wilcoxon signed-rank and Friedman tests; between-group comparisons used the Mann-Whitney U test. Exploratory correlation and regression analyses examined associations between tinnitus handicap, emotional distress, hyperacusis, age, and tinnitus duration at each assessment point.

Interventions

DEVICESteady-State Coherent Biomodulator Patch (Antinitus)

A passive, light photon-driven biomodulator patch applied behind the ear and replaced daily for three weeks, intended to influence auditory neural activity through effects on tissue water coherency.

DEVICEPlacebo Patch

A patch visually indistinguishable from the active biomodulator patch but without active photon-driven effect, applied behind the ear and replaced daily for three weeks

Sponsors

Murat Erinç
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Active and placebo patches were sealed in identical, indistinguishable envelopes by a third party, who recorded the allocation key separately. The investigator, who also served as the care provider and outcomes assessor (delivering counseling, dispensing patches, and administering weekly questionnaires), remained unaware of group allocation until the study concluded.

Intervention model description

Participants were randomly assigned in a 1:1 ratio to one of two parallel groups: an experimental group receiving the active biomodulator patch (Antinitus) or a control group receiving a visually identical placebo patch. Both groups applied their assigned patch behind the ear daily for three weeks and received the same standardized informative counseling session at study entry. Group allocation remained blinded to both participants and investigators throughout the study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Age older than 18 years Subjective tinnitus for at least 4 weeks Absence of dermatological conditions that could cause skin irritation from patch application

Exclusion criteria

Currently undergoing active tinnitus therapy Known skin sensitivity

Design outcomes

Primary

MeasureTime frameDescription
Change in Tinnitus Handicap Inventory (THI) Score from Baseline to Day 51Baseline and Day 51 (21 days post-treatment + 30 days)THI is a 25-item questionnaire (score range 0-100), with higher scores indicating greater tinnitus-related handicap.

Secondary

MeasureTime frameDescription
Change in THI Score from Baseline to Day 21Baseline and Day 21The Tinnitus Handicap Inventory (THI) is a 25-item questionnaire scored from 0 to 100, with higher scores indicating greater tinnitus-related handicap (0-16 = no handicap, 18-36 = mild, 38-56 = moderate, 58-100 = severe). Change was calculated as the difference between baseline and Day 21 scores.
Change in THI Score from Baseline to 1 YearBaseline and approximately 1 yearThe Tinnitus Handicap Inventory (THI) is a 25-item questionnaire scored from 0 to 100, with higher scores indicating greater tinnitus-related handicap. A subset of participants was contacted by telephone approximately one year after treatment to assess long-term durability of THI change from baseline.
Change in Hyperacusis Questionnaire (HQ) ScoreBaseline, Day 21, Day 51, and 1 year14-item questionnaire (score range 0-42), higher scores indicating greater hyperacusis-related distress.
Change in Hospital Anxiety and Depression Scale (HADS) ScoreBaseline, Day 21, and Day 5114-item scale divided into anxiety and depression subscales (scores ≥8 indicating increased risk).

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026